What Синекод treats: Main Uses and Benefits

The active ingredient in Sinecod is used for the symptomatic management of cough. This medication is commonly used across conditions characterized by periods of heightened symptoms that may involve irritating cough.

Symptom Focus and Benefits

Sinecod is applied across domains where additional symptomatic support is needed, primarily addressing a persistent, non-productive dry cough that creates noticeable physiological strain. The medication may be part of symptomatic management in conditions like influenza, bronchitis, and symptoms associated with whooping cough (pertussis). It is considered relevant in specialized scenarios, including the management of cough symptoms in patients before and after surgical procedures or during certain diagnostic procedures.

Therapeutic Contribution

The benefit is that it supports the patient during difficult episodes and helps improve day-to-day comfort during symptomatic periods.

“The medication is applied to address the symptomatic relief of persistent, dry coughs that may interfere with daily functioning.”

Quick Fact: Relief for Irritative Dry Cough The medication is relevant for easing cough symptoms associated with acute respiratory infections and may assist with maintaining a sense of stability when symptoms are more noticeable.

Regulatory References

1. Philippine FDA Verification Portal

Official Regulatory Eligibility for Butamirate Citrate

The eligibility profile for using Синекод (Butamirate citrate) is strictly defined by government regulatory documents, outlining populations that are permitted, contraindicated, or require caution.

Eligibility Status	Defined Population	Official Restriction Basis
Contraindicated	First Trimester Pregnancy	Absolute prohibition [1.1, 2.4]
Contraindicated	Children Under Minimum Age	Minimum age threshold enforced by formulation [1.4, 2.5]
Contraindicated	Hypersensitivity/Allergy	Known allergy to Butamirate or excipients [1.1, 1.3]
Not Recommended	Breastfeeding Mothers	Insufficient data on excretion into breast milk [1.1, 2.4]
Caution Required	Impaired Hepatic/Renal Function	Lack of safety data; risk of drug accumulation [1.1, 1.4]

Allowed Populations: Use is established for adults and adolescents, as well as children above the specific minimum age threshold defined on the product label.

Mandatory Restriction: The concomitant administration of expectorants must be avoided due to the risk of mucus accumulation. For women in the second and third trimesters of pregnancy, use is only permissible with caution and if absolutely necessary.

The official regulatory documents for Butamirate citrate define specific constraints regarding its co-administration with other medicinal products, primarily due to potential pharmacodynamic conflicts and a lack of comprehensive pharmacokinetic data.

Pharmacodynamic Restriction

The most critical documented interaction is the Pharmacodynamic Restriction with drugs intended to increase or thin mucus. Co-administration with expectorants or mucolytics must be avoided. This is a mandatory restriction because the cough-suppressant action of Butamirate can inhibit the clearance of secretions promoted by these agents. This potential for mucus stagnation in the respiratory tract formally increases the risk of complications, including bronchospasm and secondary respiratory tract infections.

Pharmacokinetic Cautions

Regulatory labeling also includes cautions regarding predicted pharmacokinetic interactions, stemming from the fact that the effects of other substances on Butamirate exposure have not been formally investigated. Consequently, Butamirate should not be used together with strong enzyme inhibitors due to the possible risk of increased exposure of Butamirate itself. Similarly, co-administration with medicinal products that possess a narrow therapeutic index should be avoided, as there is a predicted risk that Butamirate could alter the exposure of the co-administered narrow therapeutic index drug. No contraindications or specific timing separation rules are formally listed for Butamirate with food, alcohol, or herbal products.

---

The overall profile is defined by one critical pharmacodynamic avoidance rule and restrictions based on uninvestigated pharmacokinetic risk, requiring formal avoidance statements in the labeling.

How Sinecod Works: Mechanism of Action

Синекод (Sinecod) acts through butamirate, a non-opioid compound that exerts its effects primarily on the central and peripheral pathways controlling the cough reflex. Its central action is characterized by a direct influence on the neural circuits of the medullary cough center . Butamirate initiates a central pathway modulation resulting in the suppression of afferent signaling that normally triggers the reflex. This action modifies the inherent firing pattern within the brainstem, leading to the inhibition of central reflex activity.

A secondary pharmacodynamic domain involves influencing the physiological state of the bronchial smooth muscle. Butamirate affects mechanisms that induce relaxation of respiratory tract musculature (bronchodilation). This pathway adjustment contributes to the modulation of the physiological response to spasmogenic stimuli. Furthermore, the drug engages mechanisms that reduce the excitability of peripheral sensory nerve endings located in the lungs and airways, influencing the sensory input directed toward the central nervous system.

Official Administration Guidelines

Butamirate citrate is administered exclusively via the oral route using specific formulations—syrup, oral drops, and sustained-release tablets. The procedural use of the medicine is standardized to ensure accurate dosage and adherence to fixed schedules.

Route, Form, and Timing

All forms must be swallowed; sustained-release tablets are restricted from being crushed, chewed, or divided to maintain their intended release profile. Administration is typically specified to occur before meals. For liquid forms, the use of a calibrated measuring device is mandatory to ensure the correct volume is administered.

Labeled Dosing Regimens

Dosage is differentiated by formulation and the patient’s age group. Frequency schedules mandate consistent 24-hour intervals between doses.

Patient Group	Standard Formulation	Dosing Frequency
Adults	50 mg Sustained-Release Tablet	2 to 3 times daily (e.g., 8 to 12 hour intervals)
Adolescents (12+)	Syrup or SR Tablet	Up to 3 times daily (volume/tablet specific)
Children (2 months-12 yrs)	Oral Drops or Syrup	3 to 4 times daily (age-specific ml volume)

Procedural Constraints and Duration

Treatment is intended for short-term use and should be discontinued once the symptomatic need is resolved. If a dose is missed, it is stipulated that the subsequent dose must be taken at the next scheduled time; no double dose is to be taken to compensate. Specific guidance regarding dose adjustment for patients with renal or hepatic impairment is generally absent from official labeling.

Research Evidence / Overview of Studies for Синекод

Evidence for Use in Non-Productive Dry Cough

Butamirate citrate was studied for its use in research exploring how symptoms change over time, specifically for conditions characterized by fluctuating or episodic manifestations of a dry, persistent cough. Randomized Controlled Trials (RCTs) and comparative studies were observed in this research base. These studies monitored outcomes related to physical discomfort, such as cough frequency and intensity, and also looked at patient-reported outcomes describing perceived discomfort, like cough-related sleep quality.

Studies monitored how symptoms evolved in the observed populations, and research examined comparative data against other study arms, including placebo. Findings describe patterns observed in the studies over short, defined time intervals, usually lasting several days. The research focused heavily on episodes where symptoms become more noticeable, seeking to understand symptom patterns during phases of heightened symptom activity.

What remains uncertain is the long-term impact of using the substance. The follow-up durations were limited in most key trials, meaning long-term effects are not fully established. Furthermore, while the evidence contributes to understanding symptom patterns, the sample sizes were modest in many trials, and this factor may introduce variability in findings.

---

Evidence in Acute Respiratory Infections (ARIs)

The substance was studied for conditions associated with acute or disruptive episodes, such as cough associated with acute illnesses. These studies conducted during periods of increased symptom activity included comparative clinical trials in both adults and children. Researchers examined how outcomes describing episodic or acute changes—like the overall severity and duration of the symptomatic cough—was measured during the recovery phase of the acute illness.

Research highlights changes measured during the study period concerning the daily severity of cough and the occurrence of night-time cough episodes. Findings help contextualize how patients reported their experience of the acute cough cycle. Research examined observations linked to outcomes linked to inflammatory or irritative states in the study populations; however, these findings describe patterns observed in the studies only for short-term periods.

Evidence is limited regarding outcomes related to disease progression or the overall duration of the underlying respiratory infection. The evidence quality varies across studies, and the applicability of the findings to every specific type of acute cough etiology may be uncertain.

---

What is Still Uncertain About Синекод Research

Several key areas remain uncertain when reviewing the research for butamirate citrate. The evidence primarily addresses research exploring short-term symptom changes over a matter of days, and therefore, there is limited information for long-term outcomes or the durability of observed symptom patterns. Follow-up durations were limited across many of the core trials conducted.

Furthermore, sample sizes were modest in many of the core randomized controlled trials, and evidence quality varies across studies due to differences in how cough severity was measured across different research settings. Consequently, the evidence highlights what is known—and what is still uncertain, and it must be noted that research is ongoing to provide further context to these findings.

Key Studies & References Philippine FDA Verification Portal: Sinecod Patient Information Leaflet (PIL)

Common questions about Синекод (FAQ)

---

Q: How quickly does Синекод start to work?

According to official pharmacokinetic data, measurable concentrations of the active ingredient, butamirate, are typically detected in the bloodstream within 5 to 10 minutes after administration. The maximum concentration is usually reached within about 1 hour. This pharmacokinetic profile suggests the active ingredient becomes available to the body in a relatively short timeframe.

---

Q: Does taking Синекод make you drowsy or sleepy?

Official regulatory documents state that Синекод may cause drowsiness or dizziness. These effects are classified as rare side effects. Due to this possibility, official product information recommends caution regarding activities that demand mental alertness, such as driving or operating machinery.

---

Q: Can Синекод be taken with pain relievers like paracetamol?

Regulatory documents do not list a specific contraindication for common pain relievers such as paracetamol (acetaminophen). However, official warnings caution against combining it with strong enzyme inhibitors or medicinal products with a narrow therapeutic index.

---

Q: What happens if you accidentally take too much Синекод?

Official information indicates that butamirate generally has a broad therapeutic margin and is well tolerated. Nevertheless, in cases of suspected overdose, official guidance requires immediate medical attention.

---

Q: Can people with liver problems use Синекод?

Official guidelines state that caution is required when considering the use of this medication in individuals with impaired hepatic (liver) function. This caution is primarily due to a lack of comprehensive safety data regarding the potential for the drug to accumulate in the body in these patients.

---

Q: Are there any known severe allergic reactions associated with Синекод?

Hypersensitivity reactions have been reported in post-marketing experience with the medicine, although the exact frequency is not known. These reactions can manifest as skin issues, such as urticaria (an itchy rash). Any suspected severe allergic reaction should prompt immediate consultation with a healthcare professional.

---

Q: Can I take Синекод if I am also taking medicine for high blood pressure?

Official regulatory documents do not specify a direct interaction or contraindication with high blood pressure medications. However, they advise caution when combining Синекод with any medicinal products that possess a narrow therapeutic index, as formal interaction studies may be lacking.

---

Q: What kind of research has been done on the long-term use of Синекод?

Studies and research for butamirate primarily focus on observing short-term changes in cough symptoms, usually lasting a few days. Official product information notes that due to limited follow-up durations in key trials, long-term outcomes or the durability of symptom patterns are not fully established.

---

Q: Can I take Синекод if I have kidney issues?

Similar to liver issues, official guidelines recommend caution when using the medicine in patients with impaired renal (kidney) function. This is noted because there is a lack of comprehensive safety data concerning the potential for drug accumulation in individuals with kidney impairment.

---

Q: Can older adults use Синекод safely?

The medicine is generally established for use in the adult population, and it is considered to have a broad therapeutic margin. However, official regulatory documents do not provide specific, separate warnings or dosage adjustments solely for the geriatric population.

---

Q: Is Синекод sold as a syrup and as tablets?

Yes, official product information confirms that the active ingredient, butamirate, is prepared for oral administration in multiple dosage forms. These include syrup, oral drops, and solid tablets, including formulations designed for sustained release.

---

Q: Can I take Синекод if I have diabetes?

Liquid formulations of the medicine may contain sweeteners like sorbitol and saccharin. While the primary regulatory caution applies to people with hereditary fructose intolerance, some patient leaflets for the syrup state it is sugar-free. The final determination about suitability requires checking the specific formulation's excipients with a healthcare professional.

---

Q: Are there any common foods or drinks that interact with Синекод?

Official regulatory labeling does not list any formal contraindications or specific timing separation rules for taking butamirate with general food, common beverages, alcohol, or herbal products.

---

Q: Does Синекод contain alcohol or sugar?

The liquid formulations contain pharmaceutical excipients, such as sorbitol solution, which is a sugar substitute used as a sweetener. The official regulatory documents for the product do not list alcohol as an ingredient.

---

Q: Can taking Синекод cause stomach upset?

Yes, the product’s safety documentation lists gastrointestinal disturbances such as nausea and diarrhea as rare side effects. These reactions fall under the broader category of stomach upset that users may experience.

---

Q: Is it okay to drive after taking Синекод syrup?

Caution is advised regarding driving and operating machinery. This is because the medicine is officially documented to cause rare side effects of dizziness and drowsiness, which can impair the mental alertness required for these activities.

---

Q: How long should I wait to see a doctor if my cough doesn't improve with Синекод?

Official patient information indicates that consultation with a healthcare professional is appropriate if your cough symptoms do not improve, or worsen, after about 4 to 5 days of treatment. The medication is intended for short-term use.

---

Q: What is the maximum number of days Синекод should be taken?

The medication is intended for short-term, symptomatic relief. Official guidance states that consultation with a healthcare professional is appropriate if the cough persists after the typical short-term duration of use, which is often cited as 4 to 5 days.

---

Q: Is there a possibility of developing tolerance to Синекод over time?

Official clinical data classifies the active ingredient, butamirate, as a non-narcotic antitussive. Regulatory documents state that the substance does not induce habit-forming effects or dependence, which addresses the concern about tolerance development.

---

Q: Are there any specific warnings about using Синекод with sedatives?

While there is no specific warning against sedatives, official regulatory cautions are issued for co-administering the medicine with strong enzyme inhibitors or medicinal products that possess a narrow therapeutic index. This is due to a lack of formal investigation into these potential interactions.

---

Q: Why is Синекод not recommended for infants under a certain age?

The medicine is officially contraindicated for children under the specific minimum age threshold defined on the product label by regulatory authorities. This decision is based on the specific formulation and the lack of sufficient safety data to ensure appropriate use in very young infants.

---

Q: Is it possible to be allergic to the colorants or flavorings in Синекод syrup?

Yes, the product’s official eligibility profile contraindicates use for any individual with a known hypersensitivity or allergy to the active ingredient, butamirate, or to any of its excipients. Excipients are the inactive ingredients, which include colorants, flavorings, and sweeteners.

How to Store and Dispose of Sinecod

Storage and disposal of Sinecod (Butamirate Citrate) must adhere strictly to the conditions specified in the regulatory labeling to maintain the product's quality and ensure safety.

Official Storage Requirements

Condition	Requirement
Temperature Limit	Store at a temperature not exceeding 25 C
Protection	Keep the product in its original outer carton to protect from light and do not freeze
Child Safety	Must be kept out of the sight and reach of children

Stability and Disposal

The syrup formulation has a specified post-opening stability period: the product must be used within 6 months after the primary bottle seal is broken. Disposal of any unused or expired Sinecod must be carried out according to local regulatory requirements for pharmaceutical waste. The medication must not be thrown into wastewater or household waste.